

SUNOSI<sup>®</sup> (solriamfetol) is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the U.S. Food and Drug Administration (FDA) for adults living with excessive daytime sleepiness (EDS) related to narcolepsy or obstructive sleep apnea (OSA).

Once-daily SUNOSI<sup>®</sup> is the first and only wake-promoting agent (WPA) proven to improve wakefulness through 9 hours.<sup>1,2\*</sup>

## About SUNOSI<sup>®</sup>

SUNOSI<sup>®</sup> contains solriamfetol, a dopamine and norepinephrine reuptake inhibitor (DNRI).<sup>2</sup> Although the exact mechanism of action is unknown, SUNOSI<sup>®</sup> is thought to work by selectively inhibiting the reuptake of dopamine and norepinephrine, as seen in preclinical studies.<sup>2</sup>

- **Dopamine and norepinephrine systems** have an important role in sleep wake regulation<sup>2</sup>

In clinical studies, the 150 mg dose of SUNOSI<sup>®</sup> significantly improved wakefulness at 12 weeks.<sup>3</sup>

**82%** improvement in people with OSA. Compared to 0% with placebo.

**118%** improvement in people with narcolepsy. Compared to 5% with placebo.

## SUNOSI<sup>®</sup> Patient Support



### Support and More:

- The SUNOSI<sup>®</sup> On My Side Program allows patients to sign up to receive helpful tips and resources, including real life-experiences from SUNOSI<sup>®</sup> patients, delivered directly to their inbox.
- The SUNOSI<sup>®</sup> Copay Card helps eligible commercially-insured patients afford their medication.



## About EDS Related to OSA and Narcolepsy

EDS is a symptom of both OSA and narcolepsy. This condition can make people overwhelmingly tired during the day.<sup>5</sup>

### Excessive Daytime Sleepiness due to Obstructive Sleep Apnea:

- Even if you're using continuous positive airway pressure (CPAP) at night, there may be more you can do if you're still feeling tired during the day.
- Millions of people are impacted by excessive daytime sleepiness due to obstructive sleep apnea (OSA)—a real medical condition that may be treated.

### Excessive Daytime Sleepiness due to Narcolepsy:

- Everyone living with narcolepsy experiences excessive daytime sleepiness.

### COMMON SIGNS AND SYMPTOMS INCLUDE:

**Sleep Attacks**  
irresistible urge to sleep<sup>†</sup>

**Frequent Tiredness**  
trouble staying awake and alert during the day

**Unrefreshing Sleep**  
feeling tired regardless of how long you've slept

**Brain Fog**  
difficulty keeping attention and focus during the day

<sup>†</sup> Sleep attacks are a symptom of Narcolepsy only.

## Indication and Important Safety Information

SUNOSI<sup>®</sup> (solriamfetol) is a prescription medicine used to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea (OSA).<sup>2</sup>

### Limitations of Use

SUNOSI<sup>®</sup> does not treat the underlying cause of OSA and SUNOSI<sup>®</sup> does not take the place of any device prescribed for OSA, such as a continuous positive airway pressure (CPAP) machine. It is important that you continue to use these treatments as prescribed by your healthcare provider.<sup>2</sup>

### Important Safety Information

Do not take SUNOSI<sup>®</sup> if you are taking, or have stopped taking within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI).

Before taking SUNOSI<sup>®</sup>, tell your doctor about all of your medical conditions, including if you:

- have heart problems, high blood pressure, kidney problems, diabetes, or high cholesterol.
- have had a heart attack or a stroke.
- have a history of mental health problems (including psychosis and bipolar disorders), or of drug or alcohol abuse or addiction.
- are pregnant or planning to become pregnant. It is not known if SUNOSI<sup>®</sup> will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SUNOSI<sup>®</sup> passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take SUNOSI<sup>®</sup>.

### What are the possible side effects of SUNOSI<sup>®</sup>?

SUNOSI<sup>®</sup> may cause serious side effects, including:

- **Increased blood pressure and heart rate.** SUNOSI<sup>®</sup> can cause blood pressure and heart rate increases that can increase the risk of heart attack, stroke, heart failure, and death. Your doctor should check your blood pressure before, and during, treatment with SUNOSI<sup>®</sup>. Your doctor may decrease your dose or tell you to stop taking SUNOSI<sup>®</sup> if you develop high blood pressure that does not go away during treatment with SUNOSI<sup>®</sup>.
- **Mental (psychiatric) symptoms including anxiety, problems sleeping (insomnia), irritability, and agitation.** Tell your doctor if you develop any of these symptoms. Your doctor may change your dose or tell you to stop taking SUNOSI<sup>®</sup> if you develop side effects during treatment with SUNOSI<sup>®</sup>.

The most common side effects of SUNOSI<sup>®</sup> include:

- headache
- nausea
- decreased appetite
- anxiety
- problems sleeping

These are not all the possible side effects of SUNOSI<sup>®</sup>. Call your doctor for advice about side effects.

SUNOSI<sup>®</sup> (solriamfetol) is available in 75 mg and 150 mg tablets and is a federally controlled substance (CIV) because it contains solriamfetol that can be a target for people who abuse prescription medicines or street drugs. Keep SUNOSI<sup>®</sup> in a safe place to protect it from theft. Never give or sell your SUNOSI<sup>®</sup> to anyone else because it may cause death or harm them and it is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please see Medication Guide.

SUN CON ISI 05/2022

## About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians.

## References

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
2. SUNOSI<sup>®</sup> (solriamfetol) [prescribing information]. 2021. Palo Alto, CA: Jazz Pharmaceuticals.
3. Axsome Data on File.

\* As seen at week 12.

<sup>†</sup> The 75 mg dose did not show a statistically significant improvement for patients with narcolepsy-associated EDS.